Navigation Links
Can EP4 agonist alleviate gastric lesions?
Date:11/18/2009

Over 300 million patients use non-steroidal anti-inflammatory drugs (NSAIDs) in the world to treat pain, arthritis, fever and other diseases. Nearly 30% of the users suffer from gastric lesions and bleeding. To mitigate NSAIDs' adverse effects on the stomach, misoprostol, a non-selective prostaglandin E1 (PGE1) analogue, has been prescribed as the first choice for prevention of NSAID-induced injuries, but often induces severe adverse effects. There remain unmet medical needs for drugs with improved therapeutic profiles.

A research article published on November 7, 2009 in the World Journal of Gastroenterology addresses this question. A research team from United States investigated therapeutic potentials of a highly-selective EP4 agonist for treatment of a mouse gastric ulcer model in the presence or absence of indomethacin at various levels.

They found the EP4-selective agonist reduced high dose indomethacin-induced acute hemorrhagic damage and promoted mucous epithelial regeneration. Low-dose indomethacin aggravated ulcer bleeding and inflammation, and delayed the healing of the established chronic gastric ulcer. The EP4 agonist, when applied locally, not only offset indomethacin-induced gastric bleeding and inflammation, but also accelerated ulcer healing. In the absence of indomethacin, the EP4 agonist even accelerated chronic gastric ulcer healing and suppressed inflammatory cell infiltration in the granulation tissue. In vitro, the EP4 agonist protected human gastric mucous cells from indomethacin-induced apoptosis.

Their results suggest that EP4 agonists may mimic the gastric protective effects of PGE2 in the presence or absence of NSAIDs, and may show advantages over non-selective analogs such as misoprostol by minimizing adverse effects arising from activating all 4 subtype receptors of PGE2.


'/>"/>

Contact: Ye-Ru Wang
wjg@wjgnet.com
86-105-908-0039
World Journal of Gastroenterology
Source:Eurekalert

Page: 1

Related medicine news :

1. How IAP antagonist chemicals kill tumors
2. Exelixis to Receive Milestone Payment From Bristol-Myers Squibb for Achievement of Liver X Receptor Agonist Development Milestone
3. TNF-alpha antagonist stops inflammation-induced colon cancer in its tracks
4. TorreyPines Therapeutics Licenses Intellectual Property from Johns Hopkins Related to Novel Uses of Glutamate Receptor Antagonists for Prevention, Treatment of Stroke, Heart Attack
5. Galenea and Organix Announce Exclusive License Agreement for 5-HT2C Agonists for the Treatment of Obesity
6. TorreyPines NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects
7. GlaxoSmithKline Statement on FDA Advisory Committee Vote on Use of Asthma Medicines Containing Long-Acting Beta-Agonists
8. Amira Announces the Successful Completion of GLP Toxicity Studies for a Novel DP2 Antagonist.
9. Shionogi Announces Positive Top-Line Efficacy Results from Year-Long Studies of Velneperit, a Novel NPY Y5 Receptor Antagonist Being Investigated for the Treatment of Obesity
10. Arena Pharmaceuticals Announces Initiation by Merck of Phase 2 Clinical Trial of Niacin Receptor Agonist
11. FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... , ... January 17, 2017 , ... Kevin Harrington (one ... AsSeenOnTV.pro will be featuring DRTV campaigns regarding the topic of Beauty and Personal Care. ... better version of themselves. What better way to commit to these changes than beginning ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... accredited, online continuing education for EMS and firefighting professionals, has released four new ... Solution. These new courses are taught live in an online classroom and meet ...
(Date:1/17/2017)... ... ... Neil H. Greco Insurance Agency, a northern New Jersey firm that provides ... a charity drive to raise awareness of heart disease and promote habits that improve ... is responsible for 1 in every 4 deaths at the national level each year. ...
(Date:1/17/2017)... ... January 17, 2017 , ... Physicians Education Review®, LCC (PER®) ... speaker for the 34th Annual Miami Breast Cancer Conference®, on March 9-12, 2017 ... Phil Talamo, said, “We are delighted to have Sandra Lee join us as ...
(Date:1/17/2017)... Litlle Falls, NJ (PRWEB) , ... January 17, ... ... Museum and Learning Center and the Montclair State University’s Athletic Training Education program ... Montclair State University’s Athletic Training Education Program, which is consists of both ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... NEW YORK , Jan. 17, 2017 ... Summary GlobalData,s new report, "EU5 Glucose Monitoring Market ... EU5 Glucose Monitoring market. The report provides value, in ... prices (USD) within market segments - Blood Glucose Meters, ... also provides company shares and distribution shares data for ...
(Date:1/17/2017)... , Jan. 17, 2017 Paragon Bioservices received ... product development services for a variety of ... medical product development activities. The IDIQ mechanism ... pool for task order awards up to $159 ... in manufacturing and process development of biopharmaceuticals, is ...
(Date:1/17/2017)... 17, 2017  Pennsylvania Secretary of Health Dr. ... medical marijuana growers/processors and dispensaries are now available ... . Permit applications will be accepted from February ... is an important step forward in getting this ... Secretary Murphy said. "We,ve developed a thorough application ...
Breaking Medicine Technology: